RNA Binding Proteins as Potential Therapeutic Targets in Colorectal Cancer

• Published in: Cancers 2024-10, Vol.16 (20), p.3502
• Main Authors: Singh, Vikash, Singh, Amandeep, Liu, Alvin John, Fuchs, Serge Y, Sharma, Arun K, Spiegelman, Vladimir S
• Format: Article
• Language: English
• Subjects: Binding proteins; Cancer; Cancer therapies; Cell cycle; Colorectal cancer; Colorectal carcinoma; Drug targeting; Drug therapy; Gene expression; Health aspects; HuR protein; Medical prognosis; Metabolism; Metastasis; Methods; MicroRNAs; Physiology; Proteins; Review; RNA; RNA-binding protein; Roles; Stem cells; Therapeutic targets; Tumorigenesis
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16203502

RNA-binding proteins (RBPs) play critical roles in regulating post-transcriptional gene expression, managing processes such as mRNA splicing, stability, and translation. In normal intestine, RBPs maintain the tissue homeostasis, but when dysregulated, they can drive colorectal cancer (CRC) development and progression. Understanding the molecular mechanisms behind CRC is vital for developing novel therapeutic strategies, and RBPs are emerging as key players in this area. This review highlights the roles of several RBPs, including LIN28, IGF2BP1-3, Musashi, HuR, and CELF1, in CRC. These RBPs regulate key oncogenes and tumor suppressor genes by influencing mRNA stability and translation. While targeting RBPs poses challenges due to their complex interactions with mRNAs, recent advances in drug discovery have identified small molecule inhibitors that disrupt these interactions. These inhibitors, which target LIN28, IGF2BPs, Musashi, CELF1, and HuR, have shown promising results in preclinical studies. Their ability to modulate RBP activity presents a new therapeutic avenue for treating CRC. In conclusion, RBPs offer significant potential as therapeutic targets in CRC. Although technical challenges remain, ongoing research into the molecular mechanisms of RBPs and the development of selective, potent, and bioavailable inhibitors should lead to more effective treatments and improved outcomes in CRC.